[Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate].
Eleven patients with advanced adenocarcinoma of the prostate were treated with a cyclic alternating chemotherapy (VIP-DMF therapy), consisting of a three-drug combination of vincristine, ifosfamide, and peplomycin; and a three-drug combination of adriamycin, mitomycin C and 5-fluorouracil. Each cycle was repeated every 3 or 4 weeks. Of these patients, 9 were refractory to prior hormonal therapy and 8 (89%) achieved an objective response (3 partial, 6 stable) using the criteria of the U.S. National Prostatic Cancer Project. In the patients showing objective response, the duration was from 3 to 18 months with a median duration of 6 months. The survival periods from the initiation of chemotherapy in effective cases ranged from 6 to 20+ months with a median duration of 11 months. The major toxicity was myelosuppression, although no patients suffered life-threatening toxicity. We consider that VIP-DMF therapy is a useful regimen for the treatment of advanced prostatic cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D017663:Peplomycin; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
D008937:Mitomycins; D001761:Bleomycin; D016685:Mitomycin; D017663:Peplomycin; D014750:Vincristine; D004317:Doxorubicin; D005472:Fluorouracil; D007069:Ifosfamide